●    Very strong revenues increase of 13.6% at constant exchange rates, driven by:
      ○  dynamic organic growth (+7.5%) 
      ○  strategic contribution of our acquisitions (+6.1%)

●    2024 operating income2 at an all-time high of 16.6% of revenues (16.0% excluding
      acquisitions)
      ○  up by 1.5 percentage points compared to 2023 

●    Positive trend for 2025
      ○  sales growth expected between 4% and 6% at constant exchange rates and scope
      ○  operating income relatively stable at around 16%, excluding the impact of acquisitions

Our new Veterinary HPM^® digestive support wet foods have been specially designed to meet the specific needs of dogs and cats suffering from digestive disorders. Gradually available in Europe since January, they help our companions regain a better quality of daily life and facilitate their nutritional recovery in case of convalescence.

Our endocrinology offering expands with a unique solution for treating Cushing's syndrome in dogs. Available for several months in Europe, it simplifies the daily management of this hormonal disease and improves the animal's well-being.